Improving Regulatory Transparency for New Medical Therapies Act
A new act passed in the U.S. house of representative: What will it protect? Patent exclusivity, non-patent exclusivity, or both? Anything else also it deals with? The bill titled ‘A bill to amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to … Continue reading Improving Regulatory Transparency for New Medical Therapies Act
Read more »